Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31383834 | 1.00 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL30634792 | 1.00 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL15342729 | 1.00 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL25512734 | 1.00 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL25512736 | 1.00 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL2380370 | 0.92 | HSD11B1 (0.43) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL1958715 | 0.89 | HSD11B1 (0.43) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL1204992 | 0.89 | HSD11B1 (0.43) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL1204990 | 0.89 | HSD11B1 (0.43) | HSD11B1CHRM2CHRM1CHRM3ASGR1 | |
| SCHEMBL13567986 | 0.87 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2019160813-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, SLC10A1, FXR1 | HSD11B1 135/4885CHRM2 1513/4885CHRM1 1154/4885 |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, SLC10A1, FXR1 | HSD11B1 135/4885CHRM2 1513/4885CHRM1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.